Suppr超能文献

[前列腺癌的内放射治疗;耻骨后碘-125植入术令人失望的长期结果]

[Internal radiotherapy in prostatic carcinoma; disappointing long-term results of retropubic Iodine-125 implantation].

作者信息

Roeleveld T A, Horenblas S, Moonen L M, te Velde A, Meinhardt W, Bartelink H

机构信息

Nederlands Kanker Instituut/Antoni van Leeuwenhoek Ziekenhuis, Amsterdam.

出版信息

Ned Tijdschr Geneeskd. 1996 Sep 14;140(37):1855-9.

PMID:8927157
Abstract

OBJECTIVE

To evaluate the results of retropubic implantation of 1-125 seeds in patients with carcinoma of the prostate.

DESIGN

Retrospective study of records.

SETTING

Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.

METHOD

A retrospective study of records provided follow-up data on 75 patients treated in the period 1981-1990 with implantation of 1-125 seeds by a retropubic approach, preceded by pelvic lymph node dissection. Criteria for the treatment were: To, T1 or T2 carcinoma of the prostate, prostatic volume < 40 ml, no contraindications to surgery.

RESULTS

The median follow-up was 103 (60-157) months. Four patients died of complications (5%). Major postoperative complications occurred in 23% (17/75) of the cases. Residual carcinoma or distant metastasization was encountered in 43 of the 71 patients (61%). Sixteen patients died from the consequences of the prostatic carcinoma. The 5- and 10-year survival rates amounted to 74% and 42%, respectively, the cancer-specific 5- and 10-year survival rates to 85% and 67%, respectively. At the latest check-up, 18 patients were alive with tumour, 16 of them under hormonal treatment, while 21 patients were alive without indications of active prostatic carcinoma.

CONCLUSION

Treatment of carcinoma of the prostate with retropubic implantation of 1-125 seeds resulted in a high incidence of local therapeutic failure and numerous postoperative complications. These results are poorer than those of total prostatectomy and external radiotherapy.

摘要

目的

评估经耻骨后植入¹²⁵I粒子治疗前列腺癌患者的效果。

设计

记录回顾性研究。

地点

荷兰阿姆斯特丹荷兰癌症研究所/安东尼·范·列文虎克医院。

方法

一项记录回顾性研究提供了1981年至1990年期间75例接受经耻骨后途径植入¹²⁵I粒子治疗患者的随访数据,术前进行了盆腔淋巴结清扫。治疗标准为:前列腺癌为T₀、T₁或T₂期,前列腺体积<40 ml,无手术禁忌证。

结果

中位随访时间为103(60 - 157)个月。4例患者死于并发症(5%)。23%(17/75)的病例发生了严重术后并发症。71例患者中有43例(61%)出现残留癌或远处转移。16例患者死于前列腺癌相关后果。5年和10年生存率分别为74%和42%,癌症特异性5年和10年生存率分别为85%和67%。在最近一次检查时,18例患者带瘤存活,其中16例接受激素治疗,21例患者存活且无前列腺癌活动迹象。

结论

经耻骨后植入¹²⁵I粒子治疗前列腺癌导致局部治疗失败发生率高且术后并发症众多。这些结果比全前列腺切除术和体外放疗的结果更差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验